Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management ( ATTD-ASIA 2024 )
BMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells ...
| Ticker |
Sentiment |
Impact |
|
BMEA
|
Neutral
|
13 %
|
|
META
|
Neutral
|
3 %
|
